Compare ATR & DVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ATR | DVA |
|---|---|---|
| Founded | 1992 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Plastic Products | Misc Health and Biotechnology Services |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.0B | 8.2B |
| IPO Year | 1993 | 1995 |
| Metric | ATR | DVA |
|---|---|---|
| Price | $126.20 | $108.93 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 4 | 4 |
| Target Price | ★ $167.50 | $145.00 |
| AVG Volume (30 Days) | 397.7K | ★ 782.5K |
| Earning Date | 02-05-2026 | 02-02-2026 |
| Dividend Yield | ★ 1.54% | N/A |
| EPS Growth | ★ 24.99 | 5.63 |
| EPS | 6.23 | ★ 9.76 |
| Revenue | $3,662,533,000.00 | ★ $13,317,965,000.00 |
| Revenue This Year | $3.97 | $6.50 |
| Revenue Next Year | $3.36 | $2.97 |
| P/E Ratio | $20.07 | ★ $10.89 |
| Revenue Growth | 2.50 | ★ 5.14 |
| 52 Week Low | $103.23 | $101.00 |
| 52 Week High | $164.28 | $179.60 |
| Indicator | ATR | DVA |
|---|---|---|
| Relative Strength Index (RSI) | 57.20 | 44.45 |
| Support Level | $123.24 | $103.48 |
| Resistance Level | $127.22 | $106.38 |
| Average True Range (ATR) | 2.72 | 3.31 |
| MACD | 0.20 | -0.14 |
| Stochastic Oscillator | 82.83 | 54.79 |
Headquartered in Crystal Lake, Illinois, AptarGroup is a leading global supplier of dispensing systems such as aerosol valves, pumps, closures, and elastomer packaging components to the consumer goods and pharmaceutical markets. With the bulk of its annual net sales coming from Europe (49% of sales) and the United States (32%), Aptar aims to increase its presence in Asia (11%) and Latin America (8%). It operates three business segments, Pharma, Beauty, and Closures. Pharma generates over two thirds of group profits.
DaVita is the largest provider of dialysis services in the United States, boasting market share of about 35% when measured by clinics. The firm operates over 3,000 facilities worldwide, mostly in the US, and treats about 280,000 patients globally each year. Government payers dominate US dialysis reimbursement. DaVita receives about two thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business. Berkshire Hathaway owns about 45% of DaVita.